Various vaccine platforms are geared against COVID-19 vaccine development to produce immunogens in cells. To design a recombinant protein-based COVID-19 vaccine, Vaxine pty Ltd used computer models of the spike protein and its human receptor, ACE2, to identify how the virus infects human cells. Based on this, the COVAX-19Ⓡ vaccine is synthesized. It does reduce not only COVID-19 disease but also blocks virus shedding and transmission. Researchers are optimistic that this vaccine candidate could be clinically available soon with sufficient vaccine efficacy with a considerable amount of reduction in vaccination-related side effects.
No takes yet. Share an insight, caveat, or question.
Chavda et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: